Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemacabtagene ansegedleucel
- Development stage
- Phase 2
- Lead developer
- Allogene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Cemacabtagene ansegedleucel is a next-generation, allogeneic chimeric antigen receptor T cell (CAR-T) therapy targeting CD19, developed for the treatment of large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, marginal zone B-cell lymphoma, follicular lymphoma, and relapsed/refractory chronic lymphocytic leukemia (CLL). Unlike autologous CAR-T therapies that use a patient’s own cells, this “off-the-shelf” product uses donor-derived T cells engineered to express an anti-CD19 CAR. The therapy incorporates gene edits to knock out the T cell receptor gene—reducing risk of graft-versus-host disease—and the CD52 gene—conferring resistance to anti-CD52 antibody treatments used for host immune suppression. Cemacabtagene ansegedleucel has demonstrated durable responses in clinical trials and is currently in Phase II development for LBCL and CLL[1][2][3][4][5][8].
- Brand names
- cema-cel
- Other names
- cemacabtagene ansegedleucel
02
Targets
Beyond the preview
Go deeper on cemacabtagene ansegedleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemacabtagene ansegedleucel.